RWRu Wei

Ru Wei

*This is an algorithmically generated author record based on publicly available information.

Ru Wei has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

    by Jianxin Yang, Margit L MacDougall, Michael T McDowell, Li Xi, Ru Wei, William J Zavadoski, Mark P Molloy, John D Baker, Max Kuhn, Over Cabrera, et al.

    Glucagon is an important hormone in the regulation of glucose homeostasis, particularly in the maintenance of euglycemia and prevention of hypoglycemia. In type 2 Diabetes Mellitus (T2DM), glucagon levels are elevated in both the fasted and postprandial states, which contributes to inappropriate hyperglycemia through excessive hepatic glucose production. Efforts to discover and evaluate glucagon receptor antagonists for the treatment of T2DM have been ongoing for approximately two decades, with the challenge being to identify an agent with appropriate pharmaceutical properties and efficacy relative to potential side effects. We sought to determine the hepatic & systemic consequence of full glucagon receptor antagonism through the study of the glucagon receptor knock-out mouse (Gcgr-/-) compared to wild-type littermates.


  • Metabolomics and Its Practical Value in Pharmaceutical Industry

    by Ru Wei

    Metabolomics is emerging as a promising systems biology approach for many research fields including functional genomics, disease diagnosis, nutrition science, and drug discovery. Following rapid development in academic and research institutes, metabolomics is drawing an attention in the pharmaceutical industry. This review aims to highlight the practical value of metabolomics in (a) potentially validating more novel therapeutic targets and indications, (b) facilitating decision-making on the advancement of therapeutics in the drug development process, and (c) leading to better patient stratification and cost-effective clinical trials, through the application of LC/MS/MRM-based targeted metabolomics studies at a relatively low cost in pharmaceutical companies. This paper provides a brief history of the development of metabolomics and common strategies for conducting metabolomics studies. The pros and cons of the most important technologies and the major components of metabolomics studies are reviewed and discussed. Finally, selected metabolomics study examples are reviewed to illustrate how metabolomics can be used to simultaneously capture underlying biochemical changes associated with pharmaceutical interventions, and effectively produce more accurate and/or alternative efficacy and ADR biomarkers, thereby, greatly extending our knowledge of disease, protein function and drug action and maximally benefiting the pharmaceutical industry.


  • High-Throughput and Multiplexed LC/MS/MRM Method for Targeted Metabolomics

    by Ru Wei, Guodong Li, Albert B. Seymour

    Target-based metabolomics, focused on a subset of metabolites representative of key pathways, is a valuable tool for assessing metabolic changes resulting from genetic mutation, altered gene expression, and protein dysfunction in a given disease state or as a consequence of an environmental perturbation, such as a pharmaceutical. However, simultaneously analyzing hundreds of endogenous metabolites presents a challenge because of their diverse chemical structures and properties. In this study, we report a high-throughput, sensitive, and reproducible method for target-based metabolomics studies. It combines different separation conditions, optimal ionization polarities, and the most sensitive triple-quadrupole MS-based data acquisition mode (MRM). In 10 min, 205 endogenous metabolites, divided into three subgroups (amino acids, sugar and nucleic acids, and organic acids), are sequentially analyzed on a LC/MS/MRM system. Low picogram sensitivity is achieved for more than half of the metabolites. A 3−4 order of linearity and assay coefficient of variation less than 15% are observed for ∼80% of the metabolites. In summary, we have established a multiplex LC/MS/MRM method for quantitatively profiling hundreds of known metabolites from complex biological samples. The methodology is generally applicable and easily expandable to include more endogenous or drug metabolites.